Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Press Release

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program— — Company plans to announce lead molecule in first quarter of 2022 —   Vancouver, BC – November 30, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for…

Psychedelic Company Lists on NASDAQ as ‘DRUG’

In the News

Effective today—Bright Minds Biosciences shares will commence trading on Nasdaq under the ticker symbol “DRUG.” Bright Minds is already listed on the Canadian Stock Exchange (CSE:DRUG) under the same symbol. Nasdaq Stock Market LLC approved the listing of the company’s common stock on The Nasdaq Capital Market.   Bright Minds’ team of drug designers developed psychedelics…

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Press Release

Vancouver, BC – November 3, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the listing of the Company’s common stock on…